Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Future Microbiol. 2020 Mar;15:365-376. doi: 10.2217/fmb-2019-0276.
Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder caused by dysregulated immune responses against . The disorder usually complicates the course of patients with asthma and cystic fibrosis. Patients with ABPA most often present with asthma that is poorly controlled despite inhaled corticosteroids and long-acting β2 agonists. The treatment of ABPA is complicated due to the occurrence of recurrent exacerbations and spontaneous remissions. The drugs used for treating ABPA include systemic glucocorticoids, antifungal agents and biologics, each with its own benefits and drawbacks. In this review, we illustrate the treatment pathway for ABPA in different situations, using a case-based approach. In each case, we present the options for treatment based on the available evidence from recent clinical trials.
变应性支气管肺曲霉病（ABPA）是一种由针对 的免疫反应失调引起的复杂肺部疾病。该疾病通常使哮喘和囊性纤维化患者的病情复杂化。ABPA 患者最常出现的症状是尽管使用吸入皮质类固醇和长效β2 激动剂，但哮喘仍未得到良好控制。由于反复发作和自发性缓解的发生，ABPA 的治疗较为复杂。用于治疗 ABPA 的药物包括全身糖皮质激素、抗真菌药物和生物制剂，每种药物都有其自身的优缺点。在本综述中，我们通过案例分析的方法说明了不同情况下 ABPA 的治疗途径。在每种情况下，我们根据最近临床试验的现有证据提出了治疗选择。
